The production of monoclonal antibodies dates back to 1975 when Kohler and Milstein first described the fusion of immunized mouse spleen B cells with cancerous myeloma cells, resulting in hybridoma cells that are both immortal and secrete a specific antibody of interest.
Despite the reproducibility and specificity provided by mouse monoclonal antibodies, they have limited sensitivity and are susceptible to antigen heterogeneity and experimental changes in circumstances. You can also visit this site https://www.bosterbio.com/featured-products to know more about antibodies.
Rabbit monoclonal antibodies have become an important part of the antibody testing market in recent years. Driven by early successes such as in-vitro diagnostics, monoclonal rabbit antibodies are increasingly being used for research in the life sciences in addition to ongoing trials of therapeutic applications.
Image Source: Google
Scientists recognized the unique properties of these antibodies, such as greater reactivity with frequently examined animal tissues and a stronger and more diverse immune response than antibodies from mice.
While the breadth and depth of the product still do not match the traditional mouse monoclonal antibody catalog, the scientific community's search for more accurate and reliable reagents ensures continued market expansion.
The generation of monoclonal antibodies is based on the extraction of B cells from the spleen, bone marrow, or blood. Therefore, the anatomical difference of rabbits compared to mice and rats is advantageous, as these cells are present in greater numbers.
Rabbits show a naturally enhanced immune response compared to other laboratory animal species. In fact, the rabbit immune system is sensitive enough to produce strong responses to small molecules such as molecular drugs, steroid hormones, lipids, and glycolipids, as well as many natural and synthetic antigens without carrier proteins such as KLH, reducing the possibility of cross-reactivity with non-target peptide sequences.